{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:25:41Z","timestamp":1771464341825,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.urolonc.2009.01.017","type":"journal-article","created":{"date-parts":[[2009,4,13]],"date-time":"2009-04-13T02:05:57Z","timestamp":1239588357000},"page":"189-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Report of the long-term efficacy of two cycles of adjuvant bleomycin\/etoposide\/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group"],"prefix":"10.1016","volume":"29","author":[{"given":"Aristotelis","family":"Bamias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerassimos","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kastriotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerassimos","family":"Alivizatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reveka","family":"Gyftaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralambos P.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2009.01.017_bib1","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1200\/JCO.2006.07.9434","article-title":"Controversies in the management of clinical stage I testis cancer","volume":"24","author":"de Wit","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.1986.4.7.1031","article-title":"Prognostic factors in stage I nonseminomatous germ-cell testicular tumors managed by orchidectomy and surveillance: Implications for adjuvant chemotherapy","volume":"4","author":"Hoskin","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.1995.13.5.1188","article-title":"Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single-center 10-year experience","volume":"13","author":"Gels","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0022-5347(01)61926-8","article-title":"Progression detection of stage I nonseminomatous testis cancer on surveillance: Implications for the follow-up protocol","volume":"161","author":"Sharir","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib5","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0959-8049(00)00140-4","article-title":"Surveillance for stage I testicular germ cell tumours: Results and cost benefit analysis of management options","volume":"36","author":"Francis","year":"2000","journal-title":"Eur J cancer"},{"key":"10.1016\/j.urolonc.2009.01.017_bib6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.1996.14.4.1106","article-title":"Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical research Council report","volume":"14","author":"Cullen","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.urology.2003.10.023","article-title":"Long-term follow-up of Anglican Germ Cell Cancer Group surveillance vs patients with stage I nonseminoma treated with adjuvant chemotherapy","volume":"63","author":"Oliver","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2009.01.017_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00042307-199909000-00011","article-title":"Treatment of testicular tumors based on risk factors","volume":"9","author":"Schmoll","year":"1999","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1996.14.2.441","article-title":"Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial","volume":"14","author":"Pont","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib10","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/S0022-5347(05)67543-X","article-title":"Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumor","volume":"163","author":"Studer","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib11","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"28","author":"van den Belt-Dusebout","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2009.01.017_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/annonc\/mdi817","article-title":"ESMO Minimum Clinical Recommendations for diagnosis, treatment, and follow-up of mixed or nonseminomatous germ cell tumors (NSGCT)","volume":"16","author":"Huddart","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2007.12.024","article-title":"European Consensus Conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the germ cell cancer Consensus Group (EGCCCG): Part I","author":"Krege","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0022-5347(01)66972-6","article-title":"A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year follow-up","volume":"154","author":"Nicolai","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib15","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1200\/JCO.1992.10.11.1762","article-title":"Medical Research Council prospective study of surveillance for stage I testicular teratoma","volume":"10","author":"Read","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0022-5347(01)61615-X","article-title":"Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors","volume":"161","author":"Bohlen","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib17","first-page":"362","article-title":"Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer","volume":"54","author":"Moul","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2009.01.017_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2004.03.022","article-title":"Long-term efficacy of 2 cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and\/or vascular invasion","volume":"46","author":"Chevreau","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib19","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/sj.bjc.6602624","article-title":"Adjuvant bleomycin, vincristine, and cisplatin (BOP) for high-risk stage I nonseminomatous germ cell tumors: A prospective trial (MRC TE17)","author":"Dearnaley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2009.01.017_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2007.12.0899","volume":"26","author":"Albers","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.01.017_bib21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0959-8049(97)00041-5","article-title":"Risk-adapted treatment of clinical stage I nonseminoma testis cancer","volume":"33","author":"Klepp","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2009.01.017_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.urology.2003.08.045","article-title":"Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis","volume":"63","author":"Amato","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2009.01.017_bib23","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/jnci\/89.19.1429","article-title":"Risk of second malignant neoplasms among long term survivors of testicular cancer","volume":"89","author":"Travis","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2009.01.017_bib24","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1200\/JCO.1997.15.5.1837","article-title":"Importance of bleomycin combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group","volume":"15","author":"de Wit","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143909000192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143909000192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:57:16Z","timestamp":1761040636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143909000192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1078143909000192"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2009.01.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of the long-term efficacy of two cycles of adjuvant bleomycin\/etoposide\/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2009.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}